Delhi: At least 6 people trapped after four-storey building collapses, rescue operations underway
Another masterstroke by Anil Ambani, Reliance Defence to invest Rs 10000 crore in..., aim is to...
US president Donald Trump's state department begins layoffs, fires 1300 employees due to...
What is Stratus, new COVID-19 variant spreading rapidly across the globe? Here's what we know so far
Elon Musk's X cuts down subscription charges in India by up to 48%, check new prices here
New scam targets mobile phone users, doesn't require any clicks, here's how you can avoid it
Ajay Devgn breaks silence on Hindi-Marathi language controversy with his famous dialogue, says...
Union Minister Chirag Paswan receives death threat ahead of Bihar assembly polls
IND vs ENG: Joe Root scripts history, England star breaks Rahul Dravid's all-time Test catch record
Gautam Adani-led Adani Group's BIG step, set to redevelop THIS iconic ghat in...
UN issues BIG warning over Taliban's new rules for media outlets in Afghanistan, which mandates...
Radhika Yadav Killing: Autopsy report contradicts father's claim, says she died due to...
Aadhar Card enrolment to become more difficult, UIDAI will ask you to give THESE documents
'Superb initiative': Bengaluru wins hearts with plan to feed chicken and rice to stray dogs
Earthquake: Tremors felt in Delhi-NCR, second in two days
What is shortcut to become rich? ChatGPT gives an interesting answer, know its tips
Watch: Mohammed Siraj's heartfelt gesture for Diogo Jota after taking Jamie Smith's wicket at Lord's
This man retired at 45, built a fortune of Rs 4.7 crore without side hustles, fancy job
Security beefed up at Kapil Sharma's Mumbai residence after shooting at Kap's Cafe in Canada
India’s top gamers come together for an electrifying showdown hosted by Samsung
Has your name been removed from voter list? Here's how you can get it added back easily
Ratan Tata dream comes true! Tata Motors to launch Altroz EV, introduced by him in 2019
Pepe Price Prediction: If PEPE Reaches The Marketcap Of Dogecoin How Much Will You Need To Retire?
Rishabh Pant's Lord's injury: Why Dhruv Jurel cannot bat as a replacement? ICC rules explained
Google CEO Sundar Pichai praises Elon Musk's AI chatbot Grok4, he says...
Traveling to Uttarakhand? You will soon need to pre-register before going to THIS hill station
IND vs ENG: Why are England players and spectators wearing red on Day 2 at Lord's today?
Delhi's Sheesh Mahal now OPEN to tourists after 370 years; check timings, route and more
US Visa becomes more expensive, know how much you have to pay...
Indian Coast Guard bravely rescues US yacht stranded off Indira Point in Andaman and Nicobar Islands
What is ‘Solar Maximum’ and why NASA says it could affect your daily life
Rewriting Retail Reality: Engineering Smarter Data for Modern Enterprise
Solana (SOL) Price Prediction: Will SOL and Little Pepe (LILPEPE) Explode in 2025?
Artarium embraces sustainability with eco-friendly wooden tissue boxes
Radhika Yadav's music video surfaces online amid probe into Tennis player's murder by her father
Gautam Adani takes BIG step, set to transform healthcare sector, to build 1000 AI-equipped...
UK's F-35 fighter jet stuck in Kerala to finally fly home next week? Reports claim...
IND vs ENG: Ravindra Jadeja throws open challenge to Joe Root on 99, dares him to complete run
BUSINESS
US-based pharmaceutical giant Gilead Science’s in-licensing deals with eight Indian pharmaceutical players within a month for its AIDS drug.
MUMBAI: US-based the pharmaceutical giant Gilead Science’s in-licensing deals with eight Indian pharmaceutical players within a month for its AIDS drug, Tenofovir, is likely to hit market leader Cipla in the country.
Gilead has in-licensed its molecule to Matrix Laboratories, Aurobindo Pharma, JB Chemicals, Alkem, Shasun Chemicals, Strides Acrolab, Emcure and Hetero Drugs.
According to the deals, the companies would have access to Gilead’s technology to manufacture and sell Tenofovir in 95 countries including India.
Cipla, which is also marketing Tenofovir in India, is expected to reduce its price to maintain its lead in the domestic AIDS drugs market, where the competition has become intense due to the fall-out of in-licensing deals.
“Each company, with whom Gilead signed the in-licensing deals, is likely to reduce the prices to compete in the market. As the result, Cipla, the major player in the AIDS drug market, will also be forced to reduce the price to face the competition,” a pharma analyst said.
“Its move to sign more in-licensing deal is said to be calling a proxy war against Cipla, who opposed the patent application of Tenofovir in India.”
Indian AIDS patients will benefit from the price battle, he said. Cipla officials were unavailable for comments.
Gilead, which announced it would supply Viread (Tenofovir) in India with a cost lower than $1/day, is also said to be in talks with two more companies for in-licensing the Tenofovir molecule.
The patent application on Viread is currently facing a challenge from the Delhi Network of Positive People, operating under the Indian Network of People Living with HIV/AIDS.
Another advantage for Gilead in signing the deals is that the licensees cannot market the drug beyond the 95 countries mentioned in the agreement and will have to leave aside the developed countries,where Gilead itself is marketing it.
This will help Gilead to earn royalty as well as to deflect any competition from licensees. Viread registered sales of $359.2 million for the six months ended June 30. Gilead has a global patent till for Viread till 2018.